This content is in French.
CDK4/6: The double-edged sword?
2 octobre 2025
By Ana Espino | Published on october 2nd, 2025 | 3 min read
#Oncology #PinkOctober #CDK4/6 #QualityOfLife
CDK4/6 inhibitors have revolutionized the treatment of advanced or metastatic HR+/HER2- breast cancer when combined with hormone therapy. These treatments significantly prolong progression-free survival, while being oral and generally well tolerated. However, this therapeutic advancement comes with specific toxicities, sometimes underestimated, which raise practical concerns in real-world settings. Some complications, such as neutropenia, diarrhea, or cardiotoxicity, can compromise treatment continuity if not anticipated and managed quickly.
#Oncology #PinkOctober #CDK4/6 #QualityOfLife
CDK4/6 inhibitors have revolutionized the treatment of advanced or metastatic HR+/HER2- breast cancer when combined with hormone therapy. These treatments significantly prolong progression-free survival, while being oral and generally well tolerated. However, this therapeutic advancement comes with specific toxicities, sometimes underestimated, which raise practical concerns in real-world settings. Some complications, such as neutropenia, diarrhea, or cardiotoxicity, can compromise treatment continuity if not anticipated and managed quickly.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Wu, H. Y., et al. (2025). Treatment consequence and adverse events of cyclin-dependent kinase 4/6 inhibitors on patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review […]. Annals of medicine, 57(1), 2557509
View the source
